WSAAI 2022 59th Annual Scientific Session

February 6, 2022 to February 10, 2022

This year's meeting will cover novel diagnostics and therapeutics involved in severe asthma, the prevention of food allergies as well as cutting edge treatments for food allergies, address the skin as the largest immune organ and discuss other immunodeficiency and hypersensitivity disease.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and Western Society of Allergy, Asthma and Immunology (WSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.”

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 20 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commerical Support
This activity is supported by educational grants from CSL Behring, Grifols, Genentech, Optinose, AstraZeneca

Target Audience

Allergists and Allied Health Providers

Learning Objectives

Upon completion of this activity, participants should be able to:
- Recognize the different monoclonal antibody therapies for severe asthma and future agents in the drug pipeline
- Learn how gastroenterologists approach patients with mast cell disorders
- Recognize the current and potential roles of biologics to treat chronic rhinosinusitis
- Follow a world-expert in primary immunodeficiencies on how she approaches the diagnosis and treatment of PIDD

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 20.00 AMA PRA Category 1 Credit™
  • 20.00 Attendance
  • 20.00 CBRN
Course opens: 
Course expires: 
Event starts: 
02/06/2022 - 3:00pm CST
Event ends: 
02/10/2022 - 6:00pm CST

All identified conflicts of interest have been mitigated.
The individuals listed below disclose the following financial relationships:

Leonard B. Bacharier, MD
Consultant:  Astra Zeneca
Speaker: AstraZeneca, GSK, Novartis, Regeneron, Sanofi
Advisor: AstraZeneca, GSK, Novartis, Regeneron, Sanofi

Jonathan Corren, MD
Advisor: AstraZeneca, Regeneron, Sanofi
Speaker: AstraZeneca, Genentech, Regeneron, Sanofi
Consultant: AstraZeneca
Researcher: AstraZeneca, Genentech, Novartis, Regeneron, Sanofi

Jenny Murase, MD
Advisor: Leo Pharma, Sanofi

Troy R. Torgerson, MD, PhD
Advisor: Takeda
Consultant: Takeda

Steve Machtinger, MD
Speaker: Boehringer-Ingelheim

Matthew Bowdish, MD
Speaker: Boehringer-Ingelheim, GSK

Jennifer Namazy, MD
Speaker: GSK
Advisor: Genentech

David Elkayam, MD
Researcher: Novartis

Andrew White, MD
Advisor: AstraZeneca, Genentech, GSK, Regeneron/Sanofi
Speaker: AstraZeneca, GSK, Regeneron/Sanofi

Neal Jain, MD
Speaker: AstraZeneca, Sanofi‐Genzyme/Regeneron
Consultant: AstraZeneca, Novartis, Pfizer, Sanofi‐Genzyme/Regeneron
Researcher: AstraZeneca, Novartis, Sanofi‐Genzyme/Regeneron

Marc Riedl, MD, MS
Researcher: CSL Behring, Shire/Takeda
Advisor: CSL Behring, Pfizer, Regeneron, Shire/Takeda
Speaker: CSL Behring, Shire/Takeda

The following have no relevant financial relationships to disclose:

Seema S. Aceves, MD, PhD
Matthew Greenhawt, MD, MBA, MSc
Daniel Hamilos, MD
Dave Khan, MD
Gailen D. Marshall, Jr., MD, PhD
Harold S. Nelson, MD
René Anderson-Cowell, MD
Karol Anderson

Available Credit

  • 20.00 AMA PRA Category 1 Credit™
  • 20.00 Attendance
  • 20.00 CBRN
Please login or create an account to take this course.